ライフサイエンスコーパス: anti-infective agent

1 sent a target for the development of a novel anti-infective agent.

2 racellular target for the development of new anti-infective agents.

3 stance, hastening the need for selective new anti-infective agents.

4 sms and, with further development, potential anti-infective agents.

5 mportant leads for the development of potent anti-infective agents.

6 ylaxis purposes: including live vaccines and anti-infective agents.

7 d here may facilitate the development of new anti-infective agents.

8 action represents a potential target for new anti-infective agents.

9 Inhibitors of this enzyme are potential anti-infective agents.

10 applicable to the design and optimization of anti-infective agents.

11 slating this emerging modality into clinical anti-infective agents.

12 specially for applications as anticancer and anti-infective agents.

13 Therefore, the discovery of novel anti-infective agents accelerating healing of infected i

14 an emerging strategy for the development of anti-infective agents against this bacterium.

15 and could be valuable for the development of anti-infective agents against this important pathogen.

16 of Bac7, and confirming its potential as an anti-infective agent, also suggesting it may be a vehicl

17 he selection of a bifunctional peptide-based anti-infective agent and its delivery via biodegradable

18 4 died by suicide (64% had been treated with anti-infective agents and 13% had been hospitalized for

19 iberate self-harm (92% had been treated with anti-infective agents and 19% had been hospitalized for

20 d in medicine as antibiotics, anticancer and anti-infective agents and for a wide range of other appl

21 tractive drug targets for the development of anti-infective agents and herbicides.

22 associations between infections treated with anti-infective agents and infections requiring hospitali

23 Fungal endophytes are a major source of anti-infective agents and other medically relevant compo

24 otential risk factors, especially individual anti-infective agents, and that use matched controls who

25 medications: -12%, 95% CI: -3% to -21%) and anti-infective agents (antibiotics: -12%, 95% confidence

26 ance (AMR) threat, new bacterial targets and anti-infective agents are needed.

27 entists have been able to generate effective anti-infective agents based on the structural difference

28 hospitalizations with infections, prescribed anti-infective agents during childhood, parental mental

29 tion of novel targets for the development of anti-infective agents, given the importance of surface m

30 resistance and the availability of specific anti-infective agents globally, this document focuses on

31 Individuals with infections treated with anti-infective agents had an increased risk of deliberat

32 ble-blind, multicenter, clinical trials of 5 anti-infective agents in complicated intra-abdominal inf

33 ong individuals with infections treated with anti-infective agents in temporal and dose-response asso

34 lanin, represent the most important class of anti-infective agents in the treatment of serious gram-p

35 Emerging resistance of human pathogens to anti-infective agents make it necessary to develop new a

36 nal infections during pregnancy treated with anti-infective agents (n = 567,016) increased the risk o

37 aternal and paternal infections treated with anti-infective agents or hospital contacts before, durin

38 e number of maternal infections treated with anti-infective agents, particularly during and after pre

39 ptide exemplifies potentially a new class of anti-infective agents that acts on the host innate respo

40 Polymyxins are a class of lipopeptide anti-infective agents with potent and specific activity

41 dest and most clinically relevant classes of anti-infective agents, yet their complex molecular archi

42 one of medicine's most important classes of anti-infective agents; yet in contrast to many other cla